Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival
Aurore Pire,Theo Z Hirsch,Guillaume Morcrette,Sandrine Imbeaud,Barkha Gupta,Jill Pilet,Marianna Cornet,Monique Fabre,Catherine Guettier,Sophie Branchereau,Laurence Brugières,Florent Guerin,Véronique Laithier,Carole Coze,Genta Nagae,Eiso Hiyama,Pierre Laurent-Puig,Sandra Rebouissou,Sabine Sarnacki,Christophe Chardot,Carmen Capito,Cécile Faure-Conter,Isabelle Aerts,Sophie Taque,Brice Fresneau,Jessica Zucman-Rossi
DOI: https://doi.org/10.1016/j.ejca.2024.113583
IF: 10.002
2024-02-03
European Journal of Cancer
Abstract:Background Hepatoblastoma is the most frequent pediatric liver cancer. The current treatments lead to 80% of survival rate at 5 years. In this study, we evaluated the clinical relevance of molecular features to identify patients at risk of chemoresistance, relapse and death of disease. Methods All the clinical data of 86 children with hepatoblastoma were retrospectively collected. Pathological slides were reviewed, tumor DNA sequencing (by whole exome, whole genome or target) and transcriptomic profiling with RNAseq or 300-genes panel were performed. Associations between the clinical, pathological, mutational and transcriptomic data were investigated. Results High-risk patients represented 44% of our series and the median age at diagnosis was 21.9 months (range:0-208). Alterations of the WNT/ß-catenin pathway and of the 11p15.5 imprinted locus were identified in 98% and 74% of the tumors, respectively. Other cancer driver genes mutations were only found in less than 11% of tumors. After neoadjuvant chemotherapy, disease-specific survival and poor response to neoadjuvant chemotherapy were associated with 'Liver Progenitor' (p=0.00049,p<0.0001) and 'Immune Cold' (p=0.0011,p<0.0001) transcriptomic tumor subtypes, SBS35 cisplatin mutational signature (p=0.018,p=0.001), mutations in rare cancer driver genes (p=0.0039,p=0.0017) and embryonal predominant histological type (p=0.0013,p=0.0077), respectively. Integration of the clinical and molecular features revealed a cluster of molecular markers associated with resistance to chemotherapy and survival, enlightening transcriptomic 'Immune Cold' and Liver Progenitor' as a predictor of survival independent of the clinical features. Conclusions Response to neoadjuvant chemotherapy and survival in children treated for hepatoblastoma are associated with genomic and pathological features independently of the clinical features.
oncology